Calnexin as a dual-role biomarker: antibody-based diagnosis and therapeutic targeting in lung cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Lung cancer carries one of the highest mortality rates amongall cancers. It is often diagnosed at more advanced stages withlimited treatment options compared to other malignancies. Thisstudy focuses on calnexin as a potential biomarker for diagnosisand treatment of lung cancer. Calnexin, a molecular chaperoneintegral to N-linked glycoprotein synthesis, has shownsome associations with cancer. However, targeted therapeuticor diagnostic methods using calnexin have been proposed. Through 1D-LCMSMS, we identified calnexin as a biomarkerfor lung cancer and substantiated its expression in human lungcancer cell membranes using Western blotting, flow cytometry,and immunocytochemistry. Anti-calnexin antibodies exhibitedcomplement-dependent cytotoxicity to lung cancer cell lines,resulting in a notable reduction in tumor growth in a subcutaneousxenograft model. Additionally, we verified the feasibilityof labeling tumors through in vivo imaging using antibodiesagainst calnexin. Furthermore, exosomal detection of calnexinsuggested the potential utility of liquid biopsy for diagnosticpurposes. In conclusion, this study establishes calnexin as apromising target for antibody-based lung cancer diagnosis andtherapy, unlocking novel avenues for early detection and treatment.
Abstract
Lung cancer carries one of the highest mortality rates amongall cancers. It is often diagnosed at more advanced stages withlimited treatment options compared to other malignancies. Thisstudy focuses on calnexin as a potential biomarker for diagnosisand treatment of lung cancer. Calnexin, a molecular chaperoneintegral to N-linked glycoprotein synthesis, has shownsome associations with cancer. However, targeted therapeuticor diagnostic methods using calnexin have been proposed. Through 1D-LCMSMS, we identified calnexin as a biomarkerfor lung cancer and substantiated its expression in human lungcancer cell membranes using Western blotting, flow cytometry,and immunocytochemistry. Anti-calnexin antibodies exhibitedcomplement-dependent cytotoxicity to lung cancer cell lines,resulting in a notable reduction in tumor growth in a subcutaneousxenograft model. Additionally, we verified the feasibilityof labeling tumors through in vivo imaging using antibodiesagainst calnexin. Furthermore, exosomal detection of calnexinsuggested the potential utility of liquid biopsy for diagnosticpurposes. In conclusion, this study establishes calnexin as apromising target for antibody-based lung cancer diagnosis andtherapy, unlocking novel avenues for early detection and treatment.
참고문헌 (21)
- [URL]
- Siegel RL, "Cancer statistics, 2022", CA Cancer J Clin, 72, pp.7~33 (2022)
- Oberije C, "A validated prediction model for overall survival from stage III non-small cell lung cancer : toward survival prediction for individual patients", Int J Radiat Oncol Biol Phys, 92, pp.935~944 (2015)
- Bernabe-Caro R, "Current and emerging treatment options for patients with relapsed small-cell lung carcinoma : a systematic literature review", Clin Lung Cancer, 24, pp.185~208 (2023)
- Mitchell JM, "Untargeted lipidomics of non-small cell lung carcinoma demonstrates differentially abundant lipid classes in cancer vs. non-cancer tissue", Metabolites, 11, pp.740~ (2021)
- Jin S, "Emerging new therapeutic antibody derivatives for cancer treatment", Signal Transduct Target Ther, 7, pp.39~ (2022)
- Sung HJ, "Biomarkers for the lung cancer diagnosis and their advances in proteomics", BMB Rep, 41, pp.615~625 (2008)
- Dalton WS, "Cancer biomarkers--an invitation to the table", Science, 312, pp.1165~1168 (2006)
- Yin H, "Drugging membrane protein interactions", Annu Rev Biomed Eng, 18, pp.51~76 (2016)
- Vogel CL, "Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer", J Clin Oncol, 41, pp.1638~1645 (2023)
- Boonstra MC, "Selecting targets for tumor imaging : an overview of cancerassociated membrane proteins", Biomark Cancer, 8, pp.119~133 (2016)
- Karami Fath M, "Exosomebased strategies for diagnosis and therapy of glioma cancer", Cancer Cell Int, 22, pp.262~ (2022)
- Giustini NP, "Advances in treatment of locally advanced or metastatic non-small cell lung cancer : targeted therapy", Clin Chest Med, 41, pp.223~235 (2020)
- Cameron PH, "Calnexin phosphorylation attenuates the release of partially misfolded alpha1-antitrypsin to the secretory pathway", J Biol Chem, 284, pp.34570~34579 (2009)
- Okayama A, "Proteomic analysis of proteins related to prognosis of lung adenocarcinoma", J Proteome Res, 13, pp.4686~4694 (2014)
- Chen Y, "Calnexin impairs the antitumor immunity of CD4(+)and CD8(+)T cells", Cancer Immunol Res, 7, pp.123~135 (2019)
- Kobayashi M, "Calnexin is a novel sero-diagnostic marker for lung cancer", Lung Cancer, 90, pp.342~345 (2015)
- Schrag JD, "The structure of calnexin, an ER chaperone involved in quality control of protein folding", Mol Cell, 8, pp.633~644 (2001)
- Wiest DL, "Incomplete endoplasmic reticulum(ER)retention in immature thymocytes as revealed by surface expression of ER-resident molecular chaperones", Proc Natl Acad Sci U S A, 94, pp.1884~1889 (1997)
- Li HD, "Enhanced clathrin-dependent endocytosis in the absence of calnexin", PLoS One, 6, pp.e21678~ (2011)
- Myhill N, "The subcellular distribution of calnexin is mediated by PACS-2", Mol Biol Cell, 19, pp.2777~2788 (2008)